The development of precision therapies in the realm of targeted cancer therapy stands as a cornerstone based on the concept of osimertinib specificity.In treating NSCLC (NSCLC) harboring epidermal growth factor receptor mutations, particularly those with T790M resistant mutations, osimertinib, a third-line epidermal growth factor receptor TKI (TKI), has shown remarkable efficacy.For its clinical efficacy and also for minimizing side effects and enhancing patient well-being, this specificity is crucial.The following sections delve into four critical needs related to osimertinib specificity and explore how addressing these demands can open the door for…
